MorphoSys

Bio Roundup: EQRx's Ambitions, Nektar No Vote, New Frazier Fund & More

Bio Roundup: EQRx's Ambitions, Nektar No Vote, New Frazier Fund & More

1 month ago   |   Xconomy

Perhaps the most talked-about news at the JP Morgan Healthcare Conference this week was a new startup that launched with $200 million and an ambitious claim its first drug...
Read more ...

Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug

Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug

1 month ago   |   Xconomy

Two weeks after MorphoSys filed for FDA review of its experimental treatment for a form of lymphoma, the company has struck a deal with Incyte to further develop and...
Read more ...

Incyte pays $750M upfront for rights to MorphoSys cancer drug

1 month ago   |   Fierce Biotech

Incyte is set to pay MorphoSys $750 million upfront for rights to anti-CD19 antibody tafasitamab. The licensing deal, which features a $150 million equity investment and up to...
Read more ...

Pivoting from clinical to commercial, MorphoSys loses chief scientist

3 monthes ago   |   Fierce Biotech

After the loss of its longtime CEO at the start of the year, a morphing MorphoSys is now losing its chief scientific officer just as it gears up for its first commercial launch.
Read more ...

Trials of Novartis' Dupixent rival bet scrapped by MorphoSys, Galapagos

3 monthes ago   |   Fierce Biotech

MorphoSys and Galapagos are cutting off development of their Novartis-backed drug MOR106 in atopic dermatitis.
Read more ...

Celgene Adds Cell Therapies From Immatics With Bristol Sale In Sight

Celgene Adds Cell Therapies From Immatics With Bristol Sale In Sight

5 monthes ago   |   Xconomy   |   2 articles

Even as its sale to Bristol-Myers Squibb inches closer to completion , Celgene-long known for its web of biotech partnerships -has inked another alliance. Celgene will...
Read more ...

Chutes & Ladders-Frontier Medicines launches with biotech vet as CEO

7 monthes ago   |   Fierce Biotech

Frontier Medicines is launching with $67 million and a biotech vet as CEO; after being snapped up by Alexion, Syntimmune's CEO is joining MorphoSys; and Recursion has named a...
Read more ...

Bio Roundup: Merger Drama, FDA Trauma, Big IPOs, CRISPR Fights & More

Bio Roundup: Merger Drama, FDA Trauma, Big IPOs, CRISPR Fights & More

7 monthes ago   |   Xconomy

It was a busy week. If we had to choose a theme, it was all about getting together. Two huge drug companies, AbbVie and Allergan, said they'd be better as one. Two more huge...
Read more ...

After being snapped up by Alexion, Syntimmune's CEO joins MorphoSys

7 monthes ago   |   Fierce Biotech

New York rare disease biotech Syntimmune has had a roller-coaster few years, losing CEOs, gaining new ones and then being snapped up by Alexion Pharmaceuticals in 2018 for up...
Read more ...

Chutes & Ladders-Enzyvant finds new CEO in former Alexion executive

One year ago   |   Fierce Biotech

Enzyvant found a new CEO in former Alexion SVP Rachelle Jacques; Arix reappointed CEO Joe Anderson five months after launching a hunt for his replacement; and MorphoSys CEO...
Read more ...


Register you to post on BioTech Mag

Free Registration

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Invetx Fetches $15M to Develop Biologic Drugs for Man's Best Friend

Invetx Fetches $15M to Develop Biologic Drugs for Man's Best Friend

Veterinarians have a saying that a cat is not a small dog, says Invetx CEO Juergen Horn. Obviously, a dog of any size isn't the same as a human. But Horn, a veterinarian, says... Read more ...

Lundbeck's Alder Bio Bet Pays Off With FDA Approval of Migraine Drug

Lundbeck's Alder Bio Bet Pays Off With FDA Approval of Migraine Drug

A migraine drug that Lundbeck added to its pipeline via its nearly $2 billion acquisition of Alder BioPharmaceuticals won FDA approval on Friday. The drug, eptinezumab , is... Read more ...

IAmScience George Stewart

IAmScience George Stewart

By Becca Wolf | Bond LSC Medical bacteriologist, George Stewart has had a few stops along the way before he got to Bond LSC in 2004. Having done schooling and research at... Read more ...

Arima Genomics Completes Series A Financing

SAN DIEGO--Arima Genomics, Inc., a company focused on research tools to accelerate the understanding of genome sequence and structure toward their role in human health and... Read more ...

Viking Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO, Feb. 24, 2020 /PRNewswire/ - Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and... Read more ...

Molecular characterization and overexpression analyses of secologanin...

Abstract Camptothecin is a high-value anti-cancerous compound produced in many taxonomically unrelated species. Its biosynthesis involves a complex network of pathways and a... Read more ...

Modulation of the Purine Pathway for Riboflavin Production in Flavinogenic...

Riboflavin is an indispensable nutrient for humans and animals, since it is the precursor of the essential coenzymes FMN and FAD, involved in variety of metabolic reactions... Read more ...

A Critical Review of Genome Editing and Synthetic Biology Applications in...

Being the green gold of the future, microalgae and cyanobacteria have recently attracted considerable interest worldwide, for they can be used to produce different kinds of... Read more ...

Biodegradation of penicillin G from industrial bacteria residue by...

An efficient biodegradation-strengthening approach was developed to improve penicillin G degradation from industrial bacterial residue in an expanded bed adsorption bioreactor... Read more ...

More clues for how the monkeyflower got its spots

The monkeyflower, or Mimulus, though possessing a relatively simple genome is able to produce a stunning array of pigmentation patterns. A team of researchers is one step... Read more ...